Market revenue in 2023 | USD 121.2 million |
Market revenue in 2030 | USD 139.8 million |
Growth rate | 2.1% (CAGR from 2023 to 2030) |
Largest segment | Capping agents |
Fastest growing segment | Capping Agents |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Capping Agents, Nucleotides, Plasmid DNA, Enzymes |
Key market players worldwide | Roche Holding AG, Merck KGaA, Thermo Fisher Scientific Inc, Maravai LifeSciences Holdings Inc Ordinary Shares - Class A, New England Biolabs, Creative-Biolabs, Jena Bioscience, YEASEN Biotechnology, BOC Sciences, Hongene Biotechnology |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to mrna synthesis raw materials market will help companies and investors design strategic landscapes.
Capping agents was the largest segment with a revenue share of 39.19% in 2023. Horizon Databook has segmented the France mrna synthesis raw materials market based on capping agents, nucleotides, plasmid dna, enzymes covering the revenue growth of each sub-segment from 2018 to 2030.
Increasing investments by major players to develop mRNA vaccines in France is expected to boost market growth during the forecast years. For instance, in March 2022, Sanofi announced strategies to invest USD 1.02 billion over the next few years with the aim to develop a full and independent mRNA value chain in France.
Hence, investments specific to mRNA-based therapeutics in the region are anticipated to offer lucrative opportunities for the market. Moreover, rising approvals of mRNA-based vaccines in the region is projected to fuel market growth over the review period.
For instance, in September 2022, three bivalent mRNA vaccines against COVID19 Omicron variants were approved by The French National Health Authority (HAS). Thus, increasing approvals of mRNA-based vaccines by government bodies is likely to increase the demand for mRNA synthesis raw materials in the near future.
Horizon Databook provides a detailed overview of country-level data and insights on the France mrna synthesis raw materials market , including forecasts for subscribers. This country databook contains high-level insights into France mrna synthesis raw materials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account